News round-up for 4-8 August by DDW Senior Digital Content Editor Diana Turner.

In the week that the US Department of Health and Human Services cancelled multiple programmes investigating mRNA vaccines, a number of other clinical trials have made the headlines.

The top stories:

LIfT BioSciences receives €12m to support solid tumour trials

LIfT BioSciences has received a grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026.

Read more…

Plans for Phase IIb trial of EXN407 for diabetic eye disease

The Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease (CLEAR-DE) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients with non-proliferative diabetic retinopathy (NPDR).

Read more…

Partners launch trial of novel HIV vaccine in Africa

A Phase I clinical trial of a novel T cell-inducing HIV vaccine candidate has launched in Africa to evaluate immune responses to highly networked HIV T-cell epitopes.

Read more…

Mounjaro comes out on top in head-to-head trial

Lilly has shared topline results from SURPASS-CVOT, a head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.

Read more…

Data supports imlifidase prior to gene therapy for Duchenne

Hansa Biopharma has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with its imlifidase prior to receiving Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial.

Read more…